Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients
NCT04293887
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
UNKNOWN
Status
328
Enrollment
OTHER
Sponsor class
Conditions
COVID-19
Recombinant Human Interferon α1β
Interventions
DRUG:
Recombinant human interferon α1β
Sponsor
Tongji Hospital